Related Experiment Video
Updated: Oct 30, 2025

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Splice-switching as cancer therapy
Amina Jbara1, Zahava Siegfried1, Rotem Karni1
1Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, 91120, Israel.
Abstract:
In light of recent advances in RNA splicing modulation as therapy for specific genetic diseases, there is great optimism that this approach can be applied to treatment of cancer as well. Dysregulation of alternative RNA splicing is a common aberration detected in many cancers and thus, provides an attractive target for therapeutics. Here, we present and compare two promising approaches that are currently being investigated to manipulate alternative splicing and their potential use in therapy. The first strategy makes use of splice-switching oligonucleotides, whereas the second strategy uses CRISPR (clustered regularly interspaced short palindromic repeat Cas (CRISPR-associated) technology. We will discuss both the challenges and limitations of these technologies and progress being made to implement splice-switching as a potential cancer therapy.
Insights
RNA splicing modulation offers promising cancer therapies by targeting aberrant splicing. This study compares splice-switching oligonucleotides and CRISPR-Cas technology for cancer treatment, discussing challenges and progress.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Therapeutics
Background:
- Alternative RNA splicing is frequently dysregulated in cancer, presenting a therapeutic target.
- Recent advances in RNA splicing modulation for genetic diseases fuel optimism for cancer treatment applications.
Purpose of the Study:
- To compare two novel therapeutic strategies for manipulating RNA splicing in cancer.
- To evaluate the potential of splice-switching oligonucleotides and CRISPR-Cas technology in cancer therapy.
Main Methods:
- Investigating splice-switching oligonucleotides for RNA splicing modulation.
- Exploring CRISPR-Cas technology for targeting aberrant RNA splicing in cancer.
Main Results:
- Both splice-switching oligonucleotides and CRISPR-Cas technology show promise for therapeutic manipulation of RNA splicing.
- Challenges and limitations of these technologies in cancer therapy are being addressed.
Conclusions:
- RNA splicing modulation represents a viable therapeutic strategy for cancer treatment.
- Further research and development are needed to overcome challenges and implement these approaches effectively in clinical settings.
More Related Videos
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

